Published in Neurosci Lett on March 02, 2005
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
α-Synuclein in cutaneous autonomic nerves. Neurology (2013) 1.32
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol (2012) 0.97
Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol (2009) 0.96
Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol (2013) 0.92
Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol (2013) 0.91
Gender differences in Parkinson's disease: focus on plasma α-synuclein. J Neural Transm (Vienna) (2013) 0.82
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies. Sci Rep (2016) 0.78
Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One (2015) 0.77
Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis (2011) 0.76
The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans. Neurol Sci (2015) 0.75
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease. J Mov Disord (2017) 0.75
Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease. Sci Rep (2015) 0.75
Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients. J Clin Diagn Res (2015) 0.75
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A (2013) 2.89
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci (2006) 1.89
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A (2010) 1.72
Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol (2007) 1.71
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A (2014) 1.48
ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol (2010) 1.48
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci (2006) 1.23
Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci (2010) 1.22
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain (2006) 1.20
Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord (2009) 1.19
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (2013) 1.18
Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant (2003) 1.17
GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol (2003) 1.17
A pathophysiological model of freezing of gait in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.17
The current clinical management of Huntington's disease. Mov Disord (2008) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia (2008) 1.15
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord (2009) 1.14
Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord (2012) 1.14
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord (2004) 1.14
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Huntington's disease patients have selective problems with insight. Mov Disord (2006) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J Neurosci (2005) 1.12
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Exp Neurol (2008) 1.11
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Clin Pract Neurol (2007) 1.11
Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport (2004) 1.10
Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci (2003) 1.10
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol (2005) 1.09
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry (2009) 1.09
Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia (2003) 1.06
Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets (2008) 1.05
Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP. Mov Disord (2004) 1.05
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia (2002) 1.02
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs (2006) 1.01
Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell (2012) 1.01
The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia (2010) 1.01
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis (2012) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci (2002) 0.99
Intrinsic determinants of neurotoxic aggregate formation by the amyloid beta peptide. Biophys J (2010) 0.99
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.98
Top-down attentional control in Parkinson's disease: salient considerations. J Cogn Neurosci (2010) 0.98
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain (2012) 0.97
Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res (2007) 0.97
Cell therapy in Huntington disease. Neurosurg Focus (2008) 0.97
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle (2009) 0.95
Huntington's disease: changes in saccades and hand-tapping over 3 years. J Neurol (2010) 0.94
Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep (2011) 0.94
Cell-based therapies for Parkinson's disease. Expert Rev Neurother (2011) 0.92
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis (2006) 0.92
Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta (2008) 0.92
The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry (2013) 0.92
Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus (2011) 0.92
Biomarkers in Huntington's and Parkinson's Disease. Ann N Y Acad Sci (2009) 0.91
Continuing trials of GDNF in Parkinson's disease. Lancet Neurol (2006) 0.90
Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. Neuroimage (2009) 0.90
Expression in drosophila of tandem amyloid β peptides provides insights into links between aggregation and neurotoxicity. J Biol Chem (2012) 0.90
The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. J Neurol (2005) 0.90
Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol (2009) 0.89
The cellular repair of the brain in Parkinson's disease--past, present and future. Transpl Immunol (2004) 0.89
Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. Neuropsychologia (2009) 0.89
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain (2014) 0.89